Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Azouz, P. Chetcuti, H. Hosker, D. Saralaya, H. Chrystyn (Leeds, Bradford, Steeton, United Kingdom). Consider the turbulent energy not inhalation flow when patients use dry powder inhalers (DPIs). Eur Respir J 2012; 40: Suppl. 56, 2142

Member's Comments

No comment yet.

Related content which might interest you: Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers Source: Eur Respir J 2001; 18: 780-783 Year: 2001 Do asthma patients achieve effective dosing from dry powder inhalers (DPIs)? Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005 Inhalation parameters from an integrated electronic multidose dry powder inhaler (eMDPI) Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018 Flow-dependent performance of several formoterol dry powder inhalers (DPIs) Source: Eur Respir J 2006; 28: Suppl. 50, 435s Year: 2006 Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Improving inhalation parameters through dry powder inhalers (DPIs) after an acute asthma exacerbation Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 In vitro performance characteristics of a novel multi-dose dry powder inhaler Airmax™ at different inspiratory flow rates Source: Eur Respir J 2002; 20: Suppl. 38, 541s Year: 2002 In vitro testing of two budesonide dry powder inhalers at different flow rates Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001 Peak inspiratory flow in COPD: implications for the use of dry powder inhalers Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001 The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Measurement of inspiratory flow through 3 different dry powder inhalation devices using In-check in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 493s Year: 2001 Comparison of total and fine drug particle mass generated from two dry powder inhalers (DPIs) by 4-year old children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002 Dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004 Pressurised metered dose inhalers (pMDIs) with integrated flow rate guidance. Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Assessment of peak inspiratory flow through dry powder inhalers in asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002 In vitro delivery of formoterol via a novel multi-dose dry powder inhaler, at clinically relevant inspiratory flow rates Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003 Peak inspiratory flow rate and the slope of the inhalation profile in dry powder inhalers (DPI) Source: Eur Respir J 2001; 18: Suppl. 33, 69s Year: 2001 The investigation of inhalation continuous duration for dry powder inhalers in asthmatic patients Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Ex-vivo emitted dose characteristics for combination formulations in dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003 Inspiratory profiles and consistency of behaviour regarding dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004